Physician profile
Kevin Green
NPI 1811900194
$8,492.29
in general payments reported to CMS, 2019-2025
39 companies · $1,198 in 2025
The $1,198 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,535 · 2020: $367 · 2021: $1,056 · 2022: $1,199 · 2023: $1,359 · 2024: $1,777 · 2025: $1,198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,335.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,334.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,205.03 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,119.71 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $542.54 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Scientific Affairs, LLC | $464.49 | 2022-2025 | Stelara, Remicade, Tremfya |
| Ardelyx, INC. | $401.08 | 2023-2025 | Ibsrela |
| Pfizer INC. | $263.05 | 2019-2022 | |
| Medtronic, INC. | $259.49 | 2022-2025 | Gi Genius, Endoflip |
| Genzyme Corporation | $236.69 | 2022-2025 | |
| Janssen Biotech, INC. | $220.48 | 2019-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $207.75 | 2019-2023 | |
| Evoke Pharma, INC. | $198.32 | 2023-2025 | Gimoti |
| Qol Medical, LLC | $198.08 | 2019-2024 | Sucraid, Sucraid |
| Phathom Pharmaceuticals, INC. | $159.39 | 2024 | Voquezna |
| Ipsen Biopharmaceuticals, INC | $122.15 | 2024 | Iqirvo |
| Intercept Pharmaceuticals, INC. | $85.28 | 2020-2024 | Ocaliva |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shire North American Group INC | $69.35 | 2019 | |
| Nestle Healthcare Nutrition INC. | $67.55 | 2021-2022 | |
| Braintree Laboratories, INC. | $67.35 | 2019-2022 | |
| Shionogi INC | $63.51 | 2020 | |
| Covidien LP | $61.31 | 2019 | |
| Aimmune Therapeutics, INC. | $55.58 | 2024-2025 | Zenpep |
| Amgen INC. | $48.46 | 2023 | Avsola, Amjevita |
| Allergan, INC. | $48.27 | 2019 | |
| Redhill Biopharma INC. | $46.16 | 2020-2021 | |
| Lilly USA, LLC | $32.37 | 2025 | Omvoh |
| Novo Nordisk INC | $30.55 | 2025 | Wegovy |
| Dova Pharmaceuticals | $22.84 | 2019 | |
| Organon LLC | $21.99 | 2024 | |
| Madrigal Pharmaceuticals | $21.73 | 2025 | Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $21.42 | 2022 | |
| Daiichi Sankyo INC. | $18.97 | 2019 | |
| Fresenius Kabi USA, LLC | $18.11 | 2023 | Idacio |
| Celgene Corporation | $14.38 | 2021 | |
| Mirum Pharmaceuticals, INC. | $14.19 | 2025 | Livmarli, Chenodal, Cholbam |
| Celltrion USA INC. | $13.89 | 2025 | Vegzelma |
| Ethicon US, LLC | $13.25 | 2019 | |
| Endo Pharmaceuticals INC. | $13.17 | 2019 | |
| Dynavax Technologies Corporation | $12.36 | 2019 | |
| Erbe USA INC | $12.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.